MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
7.59
-0.24
-3.07%
After Hours: 7.65 +0.06 +0.79% 17:36 12/05 EST
OPEN
7.84
PREV CLOSE
7.83
HIGH
7.93
LOW
7.45
VOLUME
3.20M
TURNOVER
--
52 WEEK HIGH
11.31
52 WEEK LOW
6.00
MARKET CAP
1.60B
P/E (TTM)
-160.4651
1D
5D
1M
3M
1Y
5Y
1D
Catalyst Watch: Spotlight on the Fed, Costco earnings, and Nasdaq 100 additions
Seeking Alpha · 6h ago
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
NASDAQ · 1d ago
BioCryst Grants New Hires Stock Options and RSUs as Inducement
Reuters · 1d ago
BIOCRYST REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 1d ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 1d ago
BioCryst Insider Makes a Major Stock Sale!
TipRanks · 2d ago
BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares
Reuters · 2d ago
BioCryst Announces Early Termination for Astria Merger
TipRanks · 2d ago
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.